The Royal College of Surgeons (RCS) rat is a wellcharacterized model of autosomal recessive retinitis pigmentosa (RP) due to a defect in the retinal pigment epithelium (RPE). It is homozygous for a null mutation in the gene encoding , a receptor tyrosine kinase found in RPE cells, that is required for phagocytosis of shed photoreceptor outer segments. The absence of Mertk results in accumulation of outer segment debris. This subsequently leads to progressive loss of photoreceptor cells. In order to evaluate the efficacy of lentiviral-mediated gene replacement therapy in the RCS rat, we produced recombinant VSV-G pseudotyped HIV-1-based lentiviruses containing a murine Mertk cDNA driven by a spleen focus forming virus (SFFV) promoter. The vector was subretinally injected into the right eye of 10-dayold RCS rats; the left eye was left untreated as an internal control. Here, we present a detailed assessment of the duration and extent of the morphological rescue and the resulting functional benefits. We examined animals at various time points over a period of 7 months by light and electron microscopy, and electroretinography. We observed correction of the phagocytic defect, slowing of photoreceptor cell loss and preservation of retinal function for up to 7 months. This study demonstrates the potential of gene therapy approaches for the treatment of retinal degenerations caused by defects specific to the RPE and supports the use of lentiviral vectors for the treatment of such disorders. Gene Therapy (2005) 12, 694-701.
Introduction
Inherited retinal degenerations, a heterogeneous group of diseases that include conditions such as retinitis pigmentosa (RP), are one of the leading causes of blindness in the Western world, affecting approximately 1 in 3500 people. The visual deficits are caused by the progressive dysfunction and degeneration of photoreceptor cells, triggered by mutations in any one of 130 different genes. To date, over 90 of these genes have been identified and the majority cause photoreceptor defects when mutated. Many of these genes are expressed specifically in photoreceptor cells and encode enzymes of the phototransduction cascade or photoreceptorspecific structural proteins or transcription factors; 1 others are ubiquitously expressed, but appear to be essential only for photoreceptor cell physiology. Some gene defects, however, cause photoreceptor dysfunction and degeneration by affecting retinal pigment epithelium (RPE) function. Since the neuroretina is devoid of blood vessels, proper functioning of photoreceptors depends on the RPE. The two cell types are intimately connected: the inner membrane of the RPE cell is folded into microvilli, which surround the photoreceptor outer segment tips. Besides delivering oxygen and nutrients from the choroid to photoreceptor cells and recycling the chromophore, the RPE is also involved in the phagocytosis of waste material, which is mainly composed of shed outer segment tips. 2 The lack of effective treatments for inherited retinal degenerations has prompted the development of novel therapeutic approaches including gene therapy. To date, most of the studies aimed at developing gene therapy for inherited retinal degenerations have focused on the treatment of photoreceptor cell defects. There are, however, a number of reasons why RPE defects may generally prove to be more amenable to treatment. The transduction efficiency of RPE cells is usually much higher than that of photoreceptor cells with efficient transduction following subretinal injection of a variety of viral vectors, including those based on adenovirus, lentivirus and adeno-associated virus (AAV). In addition, one RPE cell is in contact with a number of photoreceptors, and therefore a single transduced RPE cell might protect or restore function to several photoreceptor cells. Furthermore, partial correction of RPE function may have a significant impact on photoreceptor function and survival. Various forms of retinal degeneration are caused by RPE defects and there are a number of animal models of disease. These include a naturally occurring dog model of Leber's congenital amaurosis caused by due to a null mutation in gene encoding RPE65, and the Royal College of Surgeons (RCS) rat, which is a natural occurring animal model of autosomal recessive RP due to a null mutation in the gene encoding MERTK. Recently, Acland et al 3 have described highly effective gene replacement therapy in RPE65 À/À dogs. The retinal degeneration in the RCS rat model is more severe than that in RPE65 À/À dogs, thus making it a more difficult disease to treat.
The RPE defect in RCS rats is due to a null mutation in a gene encoding a member of the Axl subfamily of receptor tyrosine kinases, Mertk, which in the eye, is expressed only in the RPE. The role of Mertk is not yet completely understood, but in RCS rats the RPE cells are deficient in Gas6 induced outer segment phagocytosis, implying that Mertk is a specific Gas6 receptor. 4 In the absence of functional Mertk, the RPE is unable to remove the shed outer segment membrane material, which then accumulates within the subretinal space. As a result, RPE and photoreceptors lose contact and consequently photoreceptor cells are lost and the retina degenerates. The time course of retinal degeneration is very rapid. Photoreceptor cell loss occurs from postnatal day 18 onward and subretinal accumulation of debris is apparent at that time. 5 Degeneration is virtually complete after 2-3 months when little electroretinographical activity is detectable and few photoreceptor cells remain. 6, 7 Thinning and atrophy of the RPE begins after the onset of degeneration.
Vollrath et al 8 have previously shown that 1 month after subretinal injection of recombinant adenovirus (Ad) containing the Mertk gene, the number of photoreceptor cells in the RCS rat retina was two-to three-fold higher in the area of injection. The disadvantage of using Ad vectors for gene therapy is the relatively short duration of transgene expression, which has been ascribed to the immune responses generated against viral gene products. 9, 10 Use of vectors based on AAV to deliver the Mertk gene to defective RPE avoids this problem and we have recently reported AAV-mediated rescue of this model, with prolonged morphological rescue for up to 7 weeks following treatment. 11 The partial and temporary rescue we observed was probably due to a combination of factors, including insufficient transduction of the RPE, inappropriate transgene regulation and, perhaps most importantly, the 2-3 week delay in the onset of AAVmediated transgene expression. In order to try to improve the rescue, we have constructed a vesicular stomatitis virus glycoprotein (VSV-G) pseudotyped human immunodeficiency virus 1 (HIV-1) based lentiviral vector carrying a Mertk cDNA. Subretinal injection of lentiviral vectors results in specific and efficient transduction of RPE cells and long-term transgene expression. 12 However, the main potential advantage of using a lentiviral rather than AAV, vector in this particular model, which has a rapid degeneration, is the much faster onset of lentiviral-mediated transgene expression. Here we present a detailed assessment of the duration and extent of the morphological rescue and functional benefit following lentiviral-mediated gene replacement therapy.
Results
In order to evaluate the efficacy of lentiviral-mediated gene replacement therapy in the RCS rat, we produced recombinant VSV-G-pseudotyped HIV-1-based lentiviruses containing a murine Mertk cDNA under the control of the ubiquitously active spleen focus forming virus (SFFV) promoter, which we have previously shown to be active in RPE cells. We termed this recombinant viral vector LNT.SFFV.Mertk. As a control we used a similar vector, LNT.SFFV.GFP, which contained a GFP cDNA. Two subretinal injections of vector into the right eye of 10 days old RCS rats were performed; the left eye was left untreated as an internal control. We examined animals at several time points over a period of 7 months by electroretinography. The retinae of some animals were also examined histologically to investigate the effects of the treatment on retinal morphology.
Rod outer segment disc shedding follows a circadian rhythm in rats and is at its peak approximately 1.5 h after the onset of light in the morning. 13 In order to determine whether expression of a functional Mertk transgene leads to reversal of the phagocytic defect, some animals were killed 1.5 h after the onset of light in the morning, 4 weeks after injection of LNT.SFFV.Mertk. Figure 1a shows a schematic diagram of phagocytosis. EM analysis of RPE cells from wild-type rats reveals phagosomes containing outer segment debris (Figure 1b ). In untreated (not shown) and LNT.SFFV.GFP (Figure 1c) injected controls, phagosomes cannot be found in any part of the eye. In the RPE of LNT.SFFV.Mertk treated animals we observed large round or oval phagosomes packed with structures resembling rod outer segment discs ( Figure  1d ). While there were fewer phagosomes in the RPE of treated rats than in the RPE of normal rats, the phagosomes appeared to be morphologically very similar to that seen in wild-type animals ( Figure 1b) .
A characteristic feature of the RCS rat is the early accumulation followed by a slow disappearance of rod outer segment debris. In RCS rats the debris begins to accumulate at the surface of the RPE at around postnatal day 12. The outer segment zone including rod outer segment and apical debris becomes thicker than in normal rats between days 14 and 20. 6 To analyse the difference between treated RCS rat eyes in comparison to controls, thickness measurements of different layers of the retina were performed on semithin sections. Since the differences were most obvious 8 weeks after injection, all measurements were carried out at this time point. As the rate of degeneration seems to be slower in the extreme periphery, images of an area between the ora serrata and the optic nerve head, approximately in the middle of the injection site, were taken and measurements were performed in a 250-mm area using Zeiss LSM 5 software. Figure 2 summarizes the mean morphometric values of nondystrophic, LNT.SFFV.Mertk injected and untreated eyes. Consistent with the presence of phagosomes, which were packed with rod outer segment membrane waste material, in the treated areas we found a reduction in the debris layer thickness from a mean of 23 mm in untreated to a mean of 15 mm in treated areas from injected eyes (P ¼ 0.05). There was also a significant improvement in RPE thickness -from a mean of 5 mm in untreated to 7 mm in treated areas of injected eyes (P ¼ 0.034). The RPE is around 9-mm thick in eyes from wild-type animals.
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The partial restoration of RPE function also resulted in an improvement in the morphology of the neuroretina ( Figure 2 ). In addition to an improvement in outer segment morphology (Figure 3 ), we found a significant increase in outer segment length with a mean thickness of the outer segment layer of 25 mm in treated areas compared with 12 mm in untreated eyes (P ¼ 0.0074). It is approximately 30-mm thick in wild-type rats. The degeneration also normally affects the inner segments. These are reduced by around 75% (Po0.0001) in dystrophic retinae, but in treated areas the mean inner segment thickness was not significantly different from wild type (P ¼ 0.35). Finally, we found that the ONL was around three times thicker in treated areas compared with equivalent areas from untreated eyes (P ¼ 0.0002).
In order to analyse the effect of treatment on photoreceptor cell loss over time, animals were killed at various time points and semithin sections were taken throughout the eye. Photoreceptor cells were found in treated areas of injected eyes for up to 30 weeks following treatment, whereas in equivalent areas from untreated eyes and in eyes injected with LNT.SFFV.GFP few, if any, photoreceptors remained at 12 weeks ( Figure 4 ). It has been reported previously that in the RCS rat the disappearance of debris is faster in posterior parts of the retina than in the periphery and it is therefore important to compare equivalent areas throughout the eye in order to assess the overall effect of treatment on the rate of degeneration. 6 Comparison of LNT.SFFV.GFP injected RCS rat retina 4 weeks pi. In LNT.SFFV.GFP treated retinae outer segments, which reach the RPE, could not be found. Due to the phagocytic defect, shed outer segments are not internalized and accumulate at the apical surface of the RPE, resulting in the formation of a debris layer. (c) RCS rat retina 4 weeks after treatment with LNT.SFFV.Mertk. Areas with well-organized outer segments could be found throughout the treated area indicating that restoration of phagocytosis has a beneficial effect on retinal morphology.
Long-term rescue of RCS rats after gene therapy M Tschernutter et al treated and control eyes showed a reduction in the loss of photoreceptor cells in treated eyes at different time points ( Figure 5 ). While the number of photoreceptor cells in treated eyes was approximate 50% greater in the middle of the treated area than in untreated ones 4 weeks after injection of LNT.SFFV.Mertk, this difference became more obvious at 8 weeks with a two-to three-fold increase in photoreceptor number. It remained significantly higher for the duration of the study that lasted 7 months. At all time points a significant difference between either uninjected or LNT.SFFV.GFP injected eyes and LNT.SFFV.Mertk treated eyes could be found (P-values between 0.004 and 0.0001). In contrast, no significant difference could be found between untreated and LNT.SFFV.GFP injected eyes at any time point, confirming that delivery of a nontherapeutic vector has no influence on photoreceptor survival beyond 4 weeks. In order to analyse the effect of the treatment on retinal function over time we performed electroretinography (ERG). This measures the electrical response of the entire retina to a light stimulus. The ERG trace reflects the activity of several cell types in the neuroretina. However, the main part of the trace is the large corneal-positive potential b-wave generated mainly in on-bipolar cells and third-order neurons, but which correlates well with the number of functional photoreceptor cells in the eye. A flash intensity of 100 mcd s/m 2 allows the response of both rods and cones to be measured, whereas flash intensities of 10 mcd s/m 2 reflect only rod responses and at 1000 mcd s/m 2 cone responses can be measured. Long-term rescue of RCS rats after gene therapy M Tschernutter et al Figure 6a shows an ERG intensity series obtained simultaneously from the injected right and the untreated left eye of an RCS rat, 8 weeks after treatment with the therapeutic vector. In the treated eye, b-wave amplitudes were significantly increased compared with the untreated control. Oscillatory potentials (OPs) are small rhythmic wavelets of rapid low amplitude potential on the ascending limb of the b-wave, increasing in size with brighter stimuli. They represent the postsynaptical neuronal component of ERG recordings. OPs, which increase in size with brighter stimuli, could be found in the treated eye but not in the untreated contralateral controls. The pattern of the response of the treated eye to a series of increasing stimuli resembled that of the normal animal, with increasing b-wave amplitudes and decreasing b-wave latencies. A typical ERG intensity series from a wild-type (nondystrophic) rat is shown in Figure 6b .
Since both rod and cone responses can be measured at a flash intensity of 100 mcd s/m 2 , recordings of responses following this intensity were used to make a time course of electrical retinal responses from a single animal treated with LNT.SFFV.Mertk in one eye ( Figure 7 ). The traces were recorded simultaneously from the injected (right) and the uninjected (left) eye of an RCS rat. In the untreated control eye the b-wave amplitude decreased rapidly over time, disappearing completely after 8 weeks. In the treated eye the ERG response was still present at this time and was observed for more than 18 weeks after treatment, suggesting that following treatment with LNT.SFFV.Mertk photoreceptor survival was prolonged. The difference between the untreated and treated eye was most obvious at 8-12 weeks.
The average b-wave amplitudes of the ERG recordings were evaluated statistically. The LNT.SFFV.Mertk treated eyes showed a significantly higher b-wave amplitude than the contralateral untreated eye up to 27 weeks after injection (P ¼ 0.049; Figure 8a ). Maximal differences were obtained between 8 and 14 weeks after treatment. At these time points the b-wave amplitude in the eyes treated with LNT.SFFV.Mertk was approximately fourfold higher than in the untreated eye (median: 93.7 versus 22.5 mV; P ¼ 0.008). In control animals injected with LNT.SFFV.GFP, no significant difference in b-wave amplitudes between treated and untreated eye could be found at any time point (Figure 8b ). Results obtained with flash intensities of 10 and 1000 mcd s/m 2 did not differ substantially from the data presented and are not shown.
Discussion
Two previous studies have demonstrated rescue of the RCS rat using either Ad or AAV based gene replacement therapy. 8, 11 Immune responses to Ad vectors appear to limit their effectiveness in the eye to around 3 weeks. 10, 14 Although gene replacement therapy using an AAV-2 vector is more effective than that using an Ad vector, 11 the late onset of AAV-mediated expression is likely to compromise its efficacy. While AAV vectors are much less immunogenic than Ad vectors and AAV vectormediated gene transfer is generally maintained over a long period of time, by the time maximal transgene expression is attained, retinal degeneration in the RCS rat is already well advanced. Although this might have a major impact on the efficacy of treating RCS rats, this should not be a major concern for the treatment of patients. Whereas retinal degeneration in the rats is Long-term rescue of RCS rats after gene therapy M Tschernutter et al complete by 3 months, in RP patients with mutations in the Mertk gene the disease process occurs over several decades. We nevertheless wished to determine whether we could significantly improve the rescue in this model by facilitating rapid transgene expression. We have therefore evaluated gene replacement therapy using a lentiviral vector in order to determine the degree of rescue we might obtain if maximal levels transgene expression occurred before there was significant damage to the retina as a result of the phagocytic defect.
In this study we have demonstrated restoration of phagocytosis, a reduction in photoreceptor loss and a corresponding reduction in the decline in retinal function as assessed by ERG. To the best of our knowledge, this is the most significant rescue to date of a severe retinal degeneration. Compared with treatment using an AAV-2 vector, 11 which showed an improvement in the retinal response in treated eyes over a period of 9 weeks, following treatment with an HIV vector, we were able to improve retinal function for more up to 27 weeks and with significantly higher ERG b-wave amplitudes. The improvement in function did not last as long as the improvement in retinal morphology. Since an ERG is an average response from the whole eye, contributions to this response from a decreasing area of rescued retina will eventually be masked by the global response from areas that have degenerated. Treated areas covered approximately 50% of the entire retina. While retinal degeneration was not prevented, 8 weeks after treatment, there were two-to three-fold more photoreceptor cells in treated areas than in equivalent untreated areas and photoreceptor cell survival was prolonged for up to 30 weeks after treatment, 23 weeks longer than that following treatment with an AAV-2 vector. One reason why treatment did not result in better photoreceptor cell protection might be that 50% RPE transduction is insufficient to ultimately prevent degeneration in treated areas. Degenerating photoreceptor cells in other parts of the retina may have a negative impact on photoreceptor survival in treated regions. 15 Several studies have suggested that retinal metabolism is altered within the RCS rat retina and also in patients with RP. 16, 17 Changes in degenerating photoreceptors are likely to generate a microenvironment that has a negative influence on the survival of healthy cells. 15, 18, 19 Therefore, it will probably be important to treat as much of the retina as possible in the RCS rat and eventually also in patients.
RPE defects are probably the most amenable to gene therapy. Even though retinal degeneration is rapid in the RCS rat model, we were still able to slow photoreceptor cell loss. This has not yet been possible for treatment of animal models, such as the rds mouse, that have severe photoreceptor defects. 20 Preclinical trials of gene therapy for a type of Lebers congenital amaurosis (LCA), a severe form of early-onset retinal dystrophy, due to mutations in the RPE-specific RPE65 have been particularly successful 3, 21 and clinical trials of gene therapy to treat this defect are likely to be the first such trials for the treatment of retinal dystrophies. This is because this gene defect results in a severe condition and delivery to the RPE of an RPE65 transgene resulting in restoration of absent rod photoreceptor function would provide an early functional readout, long before the effect on retinal degeneration might be assessed. While there is not such a convenient functional readout following treatment of autosomal recessive RP resulting from defects in the Mertk gene, it still may be an appropriate disorder for some of the first clinical trials of gene therapy for inherited retinal dystrophies since the effect of treatment on retinal degeneration is likely to become apparent within a relatively short period of time compared with many other retinal dystrophies. These results therefore provide strong support for developing lentivirus, and indeed AAV-based, gene therapy approaches for RP patients with mutations in Mertk. Despite the partial nature of the rescue, loss of function in the treated rats could be delayed by up to 27 weeks and some photoreceptors were preserved for at least 7 months. It is difficult to predict the clinical impact of an equivalent treatment outcome in patients. Comparing the different rates of degeneration of humans and rats a similar approach in patients might delay degeneration for years rather than months. Although over the last few years there have been major advances in lentiviral vector production with regard to purification and biosafety, . After administration of the therapeutic vector, b-wave amplitudes were significantly increased between 6 and 27 weeks after treatment (Po0.05), whereas injections of LNT.SFFV.GFP did not alter the electrical response of the retina.
Long-term rescue of RCS rats after gene therapy M Tschernutter et al the use of AAV vectors raises fewer concerns about safety, and in general their production is better developed. It is therefore likely the first clinical trials of gene therapy for this disease would utilize AAV vectors. While our results provide further evidence to support gene therapy approaches for the treatment of RP, they also emphasize the requirement to treat patients at an early stage of the disease.
Materials and methods

Recombinant Lentiviral constructs
The murine Mertk mRNA was isolated from murine total retinal RNA, RT-PCR amplified 11 and cloned into a VSV-G pseudotyped HIV-1-based vector containing the Mertk gene was produced as described previously. 12, 23 The lentiviral Mertk expression construct, LNT.SFFV.Mertk, was generated by cloning the murine Mertk gene between the SFFV promoter and the WPRE element of the pHR 0 SIN-cPPT-SEW lentivirus construct. 23 In total, 12 15-cm plates subconfluent with 293T cells were transfected with 50 mg of the LNT.SFFV.Mertk construct per plate together with the lentivirus helper constructs pMD.G (17.5 mg) and pCMVR8.91 (32.5 mg). 24 The GFP control virus, LNT.SFFV.GFP, is identical to the construct pHR 0 SIN-cPPT-SEW as described by Demaison et al.
23
Transfections were performed as described using 12 ml Optimem containing 75 ml Lipofectin (Life Technologies, Paisley, UK) and 400 mg peptide 6. 25 After 5 h incubation at 371C, the transfection mixture was replaced with complete DMEM. After 24 h, the medium was replaced with 15 ml of complete DMEM medium. After 48 h, the medium was collected and cells and cell debris in the medium were spun down twice for 10 min at 2500 r.p.m. The supernatant was filtered through a 0.45 mm filter (Millipore) and centrifuged for 2 h at 23 000 r.p.m. to spin down the virus. The virus pellet is resuspended in Optimem, spun at 4000 r.p.m. for 10 min to remove remaining debris and frozen down in batches at À801C.
Treatment groups
All animal experiments have been conducted in accordance with the Policies on the Use of Animals and Humans in Neuroscience Research, revised and approved by the Society for Neuroscience in January 1995. Dystrophic and nondystrophic RCS rats were used for this study. To control for interanimal variability in the rate of degeneration, in all animals the right eye was injected with vector while the left eye remained untreated. Thus, the untreated eyes provided an internal control for all experiments. All treated eyes received two injections of viral suspension at a single time point.
Subretinal injection
We performed injections in RCS rats on postnatal day 10 (p10) as previously described. 26 Surgery was performed under direct ophthalmoscopic control through an operating microscope. The tip of a 1.5 cm, 34-gauge hypodermic needle (Hamilton, Switzerland) was inserted tangentially through the sclera of the rat eye, causing a self-sealing wound tunnel. The needle tip was brought into focus in the subretinal space and approximately 4 ml of viral suspension (10 9 viral particles/ml) was injected to produce a bullous retinal detachment in the superior and inferior hemisphere around the injection sites.
Electroretinographic analysis
ERGs from injected RCS rats were recorded in a standardized manner by the same investigator (FCS) at various time points up to 29 weeks after treatment. All animals were dark-adapted overnight (16 h) and Ganzfeld ERGs were obtained simultaneously from both eyes of each animal in order to provide an internal control. All procedures for recording were carried out under dim red light. The rats were anaesthetized with a single intraperitoneal injection of ketamine (60 mg/kg), xylazine (8 mg/kg) and atropine (0.75 mg/kg). The pupils were dilated using one drop each of phenylephrine 2.5% and tropicamide 1% to each eye. A single drop of 2% hydroxy-propyl-methyl-cellulose was placed on each cornea to keep it moisturized. ERGs were recorded using commercially available equipment (Toennies Multiliner Vision, Jaeger/Toennies, Germany) after placing monopolar corneal ring-electrodes and midline subdermal reference and ground electrodes. Bandpass filter cutoff frequencies were 1 and 300 Hz for all measurements. ) to try and minimize the dark-adapted conditioning flash effect. All data were analysed and stored using the Toennies Multiliner Vision program.
Semithin and ultrathin sections
At different time points rats were killed and their eyes were immediately removed and processed for semithin and ultrathin sections, according to a previously described method. 20 For the phagosome study, animals were killed 1 h the light onset, at 0800, to coincide with the circadian rhythm of disc shedding. Before embedding, eyes were carefully orientated in a way that both injection sides would be hit approximately in the middle of the eye, in the optic nerve area, by sectioning. It is known that degeneration progresses more rapidly in the posterior, central part of the retina than in the peripheral part and that photoreceptor cells survive longer in the superior hemisphere than in the inferior hemisphere. Sections were therefore analysed from areas between the ciliary body and the ONH, in the middle of the inferior injection site, where degeneration occurs at an intermediate pace and differences between treated and untreated eyes were more obvious. Eyes were immersion fixed in 3% glutaraldehyde and 1% paraformaldehyde buffered to pH 7.4 with 0.08 M sodium cacodylate-HCl. After a minimum of 12 h of fixation, the cornea and lens were removed. Following a washing step of the remaining segments for 15 min with 2.5% glutaraldehyde and 0.1 M cacodylate buffered to pH 7.4, the eyes were osmicated for 2.5 h in a 1% aqueous solution of osmium tetroxide in the dark, followed by dehydration steps through ascending ethanol series (70-100%, 10 min per step with rotation). After three changes of 100% ethanol, specimens were passed through propylene oxide (3 Â 10 min) and left in a 50:50 mixture of propylene oxide Long-term rescue of RCS rats after gene therapy M Tschernutter et al and araldite for a minimum of 2 h with rotation. Following a single change to fresh araldite (5 h with rotation) the specimens were embedded and cured for 48 h at 601C. Semithin (0.7 mm) and ultrathin (0.07 mm) sections were cut using a Leica ultracut S microtome fitted with an appropriate diamond knife (Diatome histoknife Jumbo or Diatome Ultrathin). Following sequential contrasting with 1% uranyl acetate and lead citrate, the ultrathin sections were analysed and photographed using a JEOL 1010 Transmission Electron Microscope operating at 80 kV. Semithin sections were stained with 1% toluidine blue and evaluated using a Leitz Diaplan microscope fitted with a Leica digital camera DC 500 for image capture.
Statistical analysis
For each animal the b-wave amplitude at 100 mcd s/m 2 was used for statistical analysis. The b-wave values (awave through to b-wave peak) of the treated (right) eye were paired with the untreated contralateral (left) eye to provide an internal control. As ERG amplitude data do not follow a normal distribution, a paired nonparametric test was used to evaluate significance (Po0.05). This method controls for interanimal variance and test-retest variance present in rodent ERGs. The result of this statistical analysis directly indicates the improvement in b-wave amplitude caused by the treatment over the whole treated group and is independent of the rate of degeneration in individual animals. For analysis of the photoreceptor cell numbers and the absolute thickness of different retinal layers an unpaired Student's t-tests was used to determine significance.
